Cabaletta Bio: Promising Clinical Progress and Strategic Advancements Drive Buy Rating
I'm PortAI, I can summarize articles.
William Blair analyst Sami Corwin has maintained a Buy rating on CABA stock due to Cabaletta Bio's promising clinical progress and strategic advancements. The company reported encouraging results from its RESET trials in autoimmune diseases, particularly in dermatomyositis and antisynthetase syndrome. Cabaletta has also secured key regulatory designations and appointed Steve Gavel as chief commercial officer, enhancing its commercial strategy. Cantor Fitzgerald also supports a Buy rating with a $30 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments